Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both MitoQ and Omega-3 have evidence — compare verdict strength side-by-side.
10-20mg daily
morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
Acute to 6 weeks
4 weeks
12 months
3 weeks
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5/10) and wins in 2 of 3 categories.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 45).
No known interactions between MitoQ and Omega-3 have been documented in our database. However, always consult a healthcare provider before combining supplements.